Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,165.08
(
0.00%
)
US TECH 100
26,536.80
(
-0.07%
)
Dow Jones
49,310.32
(
0.00%
)
Brent Oil
101.48
(
-0.05%
)
Bitcoin
77,869.16
(
-1.00%
)
News Focus
News Focus
Post# of 823018
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

HyGro

Send PM Follow Ignore
Followers 24
Posts 4176
Boards Moderated 0
Alias Born 12/18/2019

HyGro

Re: SkyLimit2022 post# 548324

Tuesday, 12/13/2022 1:44:26 PM

Tuesday, December 13, 2022 1:44:26 PM

Post# of 823018
The validity of the trial data is critical to the Risk/Benefit. If the data is questionable after their review of the trial deficiencies that the Risk/Benefit is clear. Been the same for many biotechs that failed their regulatory review.
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NWBO News
More NWBO News